Full-Time

Federal Account Liaison-Vaccines

Confirmed live in the last 24 hours

Deadline 8/31/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

Compensation Overview

$147k - $212.3k/yr

Senior, Expert

Seattle, WA, USA + 3 more

More locations: Washington, DC, USA | Alexandria, VA, USA | Atlanta, GA, USA

Remote

Travel required approximately up to 60% to customer sites and for internal meetings.

Category
Customer Success
Strategic Account Management
Sales & Account Management
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree required.
  • Advanced or master’s degree preferred.
  • Must have demonstrated leadership skills with experience working at or working with HHS or similar Federal/Public Health Agency for a minimum of 5 years.
  • Knowledge and experience in working with coalitions, patient advocacy groups, etc.
  • Excellent written and verbal English communications skills; ability to communicate with colleagues at all levels of the organization; strong presentation skills required.
  • Demonstrated strong organizational skills: time management and project management.
  • Knowledge of Federal Acquisition Regulations and Contracting.
  • Minimum of 5+ years of progressive experience in pharmaceutical/biotech account management, field sales, or healthcare contracting, demonstrating consistent success and leadership.
  • Exceptional problem-solving skills through a collaborative approach, capable of working on complex and abstract problems of diverse scope.
  • Strong interpersonal skills including active listening, advising, facilitating, and influencing at all levels and in diverse settings.
  • Highly organized with advanced organization skills and the ability to effectively manage multiple priorities in a fast-paced environment.
  • Exceptional business acumen, strategic agility, strong analytical and conceptual thinking combined with entrepreneurial qualities.
  • Ability to work collaboratively with others and influence peers and educate management regarding account needs.
  • Strong customer-facing skills and demonstrated negotiating capability.
  • Builder with a beginner’s mind, able to combine institutional knowledge with creativity and data for continuous improvement.
Responsibilities
  • Develop and maintain relationships with key government agencies to ensure the successful commercial presence in promotion and distribution of our vaccine products with a core focus on State Awardees, Immunization Coalitions, and state chapters of Professional Organizations through translation of a top down and bottom-up strategy.
  • Manage multiple projects simultaneously and meet deadlines.
  • Co-create and execute strategic and tactical plans under tight timelines to grow and maintain existing and grow new business.
  • Demonstrate executive presence during key external stakeholder engagements while representing Sanofi brand teams.
  • Achieve key milestones and business objectives working with peers and colleagues with and without direct authority including close alignment with Public Affairs, Market Access, Government Affairs and Sales.
  • Call on customers with a regular cadence to drive business objectives forward.
  • Develop and utilize a feedback loop both internally and externally to ensure movement on the customer adoption spectrum.
  • Responsible for market intelligence and input to help shape solicitation requirements for federal bids within assigned customer base.
  • Provide timely and accurate information to healthcare providers regarding product availability, usage, and administration guidelines.
  • Collaborate with the Strategic Account Management to identify opportunities for growth and assist in the development of sales strategies and execution plans at the federal and state level.
  • Demonstrated ability to lead and collaborate effectively within a matrix organization, balancing aligned cross-functional priorities, influencing without direct authority, and driving alignment across diverse teams and stakeholders.
  • Co-create and participate in training sessions and educational programs for healthcare providers and internal teams to enhance their knowledge, understanding, and utilization of Sanofi vaccine products.
  • Monitor market trends, competitor activities, and customer feedback to identify opportunities for business growth.
  • Ensure all activities are conducted in compliance with regulatory requirements and company policies.
  • Prepare and submit regular reports on account activities, sales performance, and market insights to the management team.
  • Successfully implement co-solutioning projects with designated complex federal agencies and state awardees.
  • Provide expert industry guidance related to customer procurement options and contract vehicles.
  • Assemble and lead cross-functional teams towards a shared vision of success achieving measurable progress on integrated projects.
Desired Qualifications
  • Exposure and/or experience in other functional areas of the business (e.g., Sales Training, Customer Solutions, Sales Operations, Distribution, and Marketing) is preferred.
  • Strong understanding of managed market dynamics and competitive landscape in the acute care and/or vaccine space is preferred.

Sanofi provides healthcare solutions through its focus on pharmaceuticals and biotechnology. The company develops treatments and vaccines aimed at addressing medical needs in areas like immunology, oncology, and rare diseases. Sanofi's products work by utilizing advanced research and development to create effective therapies and vaccines that improve health outcomes. What sets Sanofi apart from its competitors is its strong emphasis on R&D, strategic partnerships, and a diverse product pipeline, allowing it to deliver a wide range of prescription medicines and vaccines globally. The company's goal is to enhance the quality of life for people worldwide by providing patient-centric healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's acquisition of Blueprint Medicines expands its rare immunological disease portfolio.
  • The FDA approval of Dupixent addresses a large unmet need in dermatology.
  • Sanofi's 20% profit growth in Q1 2025 highlights effective market strategies.

What critics are saying

  • Increased competition in immunology could impact Sanofi's market share.
  • Potential delays in regulatory approvals may affect new product launches.
  • Integration challenges from acquisitions could disrupt operations and delay synergies.

What makes Sanofi unique

  • Sanofi's R&D focuses on unmet needs in immunology, oncology, and rare diseases.
  • The company leverages strategic partnerships to enhance its innovative treatment pipeline.
  • Sanofi's global reach allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Investors Hangout
Jul 1st, 2025
Adagene Secures $25M Investment from Sanofi

Adagene Inc. has secured a strategic investment of up to $25 million from Sanofi to advance its research and development, particularly for the clinical trials of muzastotug (ADG126), an anti-CTLA-4 SAFEbody targeting microsatellite stable colorectal cancer. This funding will extend Adagene's operational runway into 2027 and includes a phase 2 trial with over 100 patients. The partnership also allows Sanofi a role in Adagene's Scientific Advisory Board.

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...